GSK plc confirmed on September 18, 2024, that it reached confidential settlements in separate bladder and colorectal cancer cases in California, while not admitting liability. The company will continue to defend against the ongoing litigation concerning its product ranitidine, citing that studies show no reliable evidence linking it to cancer.